PINK1/PARKIN signalling in neurodegeneration and neuroinflammation

Table 1 Summary of the PARKIN and PINK1 gene augmentation viral vectors

Viruses	Capsid serotype	Promoter	Sequence	Injection place	Volume injected	Dose	Disease model	Animal	References
Lentivirus	HIV-1 based vector with VSVG envelops	PGK	Rat Parkin	S.N.	2.5 µl	3.6 × 10⁸ pg of p24 per ml	α-synuclein rat model for PD	Wistar rats	[52]
Lentivirus	HIV-1 based vector with VSVG envelops	CMV	Human PARKIN	S.N.	2 µl	10⁸ pg of p24 per ml	6-Hydroxydopamine rat model for PD	Rats	[53]
AAV	2/2	CBA	HA-tagged-PARKIN	S.N.	2 µl	3.6 × 10¹² vg/ml	MPTP-treated mice, a model for sporadic PD	C57BL/6 mice	[54]
AAV	2/2 and 2/5	CMV/CBA	Human PARKIN	S.N.	2 × 2 µl	2.6 × 10¹² vg/ml	6-Hydroxydopamine rat model for PD	Rats	[55]
AAV	2/2	CMV/CBA	Human PARKIN	S.N.	4 µl	5 × 10¹² vg/ml	Tau-induced dopaminergic degeneration rat model for PD	Sprague–Dawley rats	[56]
AAV	2/6	PGK	Rat Parkin	S.N.	2 µl	4.7 × 10¹⁰ TUs/ml	Methamphetamine induced neurotoxicity rat model for PD	Sprague–Dawley rats	[57]
AAV	2/8	CMV	Human PARKIN	S.N.	2 µl in mice 3 µl in rats	2.0 × 10¹¹ vg/ml	T240R-PARKIN induced dopaminergic degeneration model for PD	C57BL/6 J mice Wistar rats	[58]
AAV	2/2	CMV	Rat Parkin	Vitreous	5 µl	1.0 × 10¹³ vg/ml	Chronic hypertensive glaucoma model	Sprague–Dawley rats	[30]
AAV	2/1	CMV	Human PARKIN	Striatum	3 µl in rats 5 × 10 µl in monkeys	7.0 × 10¹² vg/ml	α-synuclein rat model for PD	Sprague–Dawley rats Macaque monkeys	[59]
AAV	2/2	CMV	Human PINK1	Hippocampus	2 µl	5.0 × 10¹² vg/ml	mAPP mouse model for AD	mice	[60]

AAV Adeno-associated virus, CBA hybrid cytomegalovirus immediate/early enhancer-chicken β-actin, CMV cytomegalovirus, PGK phosphoglycerate kinase, S.N. substantia nigra, TU transducing units, Vg viral genomes, VSVG vesicular stomatitis virus

ISSN: 2051-5960